

Supplementary Table 1

Viability is reduced in mice with *S1pr2* mutation.

Genetic background	Age	Matings (F × M)	Number of postnatal mice	S1pr2 Genotype (percentage)		
				+/+	+/-	-/-
F1N3	4 weeks after birth	+/- × +/-	179	49(27)	102(57)	28(16)
F1N7	4 weeks after birth	+/- × +/-	122	45(37)	69(57)	8(6)

The total number and percentage of mice from *S1pr2*^{+/-}*Apoe*^{-/-} crosses identified in each generation at week 4. In F1N7 generation, only 6% of the offspring were homozygous for *S1pr2*, which was much less than the expected value of 25%, while the percentage of *S1pr2*^{+/-}*Apoe*^{-/-} mice in F1N3 generation was 16%.

Supplementary Table 2

Plasma cholesterol, triglyceride, and S1P levels in *S1pr2^{+/+}Apoe^{-/-}* and *S1pr2^{-/-}Apoe^{-/-}* mice

Genotype	n	Total Cholesterol (mg/dl)	Triglyceride (mg/dl)	Sphingosine-1-phosphate (nM)
<i>S1pr2^{+/+} Apoe^{-/-}</i>	6	1492 ± 284	154 ± 23	778 ± 56
<i>S1pr2^{-/-} Apoe^{-/-}</i>	5	1549 ± 291	107 ± 22	786 ± 112

Mice (F1N3 background) were fed HCD for 12 weeks. All data are expressed as means ± SEM.

Supplementary Table 3

Body weight and food intake

Genotype	n	Body Weight (6-week old / 18-week old)* (g)	Food Intake (g / 30g BW)#
<i>S1pr2^{+/+}</i> <i>Apoe^{-/-}</i>	11	21 ± 4 / 32 ± 4	6.4 ± 1.6
<i>S1pr2^{-/-}</i> <i>Apoe^{-/-}</i>	8	19 ± 4 / 29 ± 5	5.9 ± 2.1

*HCD started at 6-week old and ended at 18-week old.

#BW, body weight; food intake was corrected for body weight.

All mice were from F1N3, and the results are presented as means ± SEM.

Supplementary Table 4

Peripheral blood counts of erythrocytes and leukocytes

	n	rbc*	Leukocyte cell	Differential White Blood Cell Count(%)		
		Number ($\times 10^4/\text{mm}^3$)	Number ($\times 10^2/\text{mm}^3$)	Lymphocyte	Monocyte	Neutrophil
<i>S1pr2^{+/+}</i>	8	691 \pm 50	35 \pm 3	78.5 \pm 2.4	2.5 \pm 0.7	18.1 \pm 2.0
<i>Apoe^{-/-}</i>						
<i>S1pr2^{-/-}</i>	7	735 \pm 78	37 \pm 6	83.7 \pm 1.3	3.2 \pm 1.1	12.3 \pm 2.2
<i>Apoe^{-/-}</i>						

*rbc= red blood cell

All results are presented as means \pm SEM.

Mice (F1N3 background) were fed HCD for 12 weeks.

Supplementary Table 5

RT-PCR primers


Gene symbol		Primer sequence (5' to 3')	Annealing temp.* (°C)	Product size (bp)
S1pr1	F	TCCATGTAAACTGGGTCAAG	60	315
	R	AAAGGTGCTGTAGGGGTTAG		
S1pr2	F	TTTTAAAATTGGGACAGGGT	60	258
	R	TTCTCCACAGGATTTAGCAA		
S1pr3	F	ATGGCATTGCTCTTGTTTA	60	234
	R	TATTTTTCCCTTAACCCAGC		
S1pr4	F	AACTGTGGGTATGACTCTGG	60	190
	R	ATACAGTTGGAACAGTTGGG		
S1pr5	F	CTAGGTCTGGAAATTTGGCT	60	319
	R	AACTGAAGTTGCCAGAATCA		
Vcam1	F	GCAGAGACTTGAAATGCCTGTG	57	340
	R	CTTCGTTCCAGCTTCCCAGAGCC		
Icam1	F	TGCGTTTTGGAGCTAGCGGACCA	60	300
	R	CGAGGACCATACAGCACGTGCAG		
Gapdh	F	TGATGGGTGTGAACCACGAG	54	521
	R	GTCATTGAGAGCAATGCCAG		

* temp.=temperature. F, forward primer. R, reverse primer.

Supplementary Table 6


Real-time PCR primers

Gene symbol	ID number
Tnf	Mm00443258_m1
Il6	Mm00446190_m1
Cd36	Mm00432403_m1
Scara	Mm01313828_m1
Scarb1	Mm00450236_m1
S1pr1	Mm00514644_m1
S1pr2	Mm02620208_m1
S1pr3	Mm00515669_m1
Sphk1	Mm00448841_m1
Sphk2	Mm00445020_m1
Spp1	Mm00473016_m1
Spl1	Mm00486079_m1
Ccl2	Mm99999056_m1
Abca1	Mm00442663_m1
Abcg1	Mm00437390_m1
Ifng	Mm99999071_m1
Pparg	Mm01184323_m1
Vcam1	Mm01320970_m1
Icam1	Mm00516024_m1
Nr1h3(LXR α)	Mm00443454_m1
Nr1h2(LXR β)	Mm00437265_m1
Csf2(GM-CSF)	Mm01290062_m1
CD3e	Mm01179194_m1
IL10	Mm00439614_m1
18S rRNA	Hs99999901_s1




Supplementary Figure 1.

(A) Distribution of cholesterol in the plasma of *S1pr2*^{+/+}*Apoe*^{-/-} (closed circle) and *S1pr2*^{-/-}*Apoe*^{-/-} (open square) mice fed with HCD for 12 weeks. No difference in the distribution of cholesterol in plasma lipoproteins was detected (CM: chylomicron). (B) H&E staining of sections of livers isolated from *S1pr2*^{+/+}*Apoe*^{-/-} and *S1pr2*^{-/-}*Apoe*^{-/-} mice fed with HCD. (C) Serum ALT levels in *S1pr2*^{+/+}*Apoe*^{-/-} (closed circle) and *S1pr2*^{-/-}*Apoe*^{-/-} (open square) mice fed with HCD and *S1pr2*^{+/+}*Apoe*^{-/-} fed with normal chow (N.C.). (n=5 each).




Supplementary Figure 2.

(A) Representative Oil red O staining of spread aortas from *S1pr2*^{+/+}*ApoE*^{-/-} ($n=12$) and *S1pr2*^{-/-}*ApoE*^{-/-} ($n=10$) female mice (N3 generation) fed HCD for 8 and 16 weeks. (B) Quantified plaque areas over total aortic areas are shown. $**P<0.01$. (C) The mRNA expression levels of TNF- α , IL-6, IL-10, IFN- γ and MCP-1 that were corrected by CD3 mRNA levels ($n=5$ each).




Supplementary Figure 3.

(A-C) Colocalization staining of ECs, Macrophages. **(A)** CD31(green), VCAM-1(red) stainings colocalized ECs. **(B)** Freshly migrated macrophages are shown by costaining CCR2(green) and VCAM-1(red). **(C)** Macrophages are shown by staining Mac-3(green) and VCAM-1(red).



Supplementary Figure 4.


Expression of S1PR2 in normal and atherosclerotic aortas detected by LacZ activity in $S1pr2^{LacZ/LacZ}Apoe^{+/+}$ and $S1pr2^{LacZ/LacZ}Apoe^{-/-}$ mice. (A) X-gal (blue) staining of a cross section of the normal abdominal aorta from $S1pr2^{LacZ/LacZ}Apoe^{+/+}$ mice showing that S1PR2 is expressed in both ECs and SMCs. (B-D) Histological staining of the atherosclerotic aortas from $S1pr2^{LacZ/LacZ}Apoe^{-/-}$ mice fed HCD for 12 weeks. X-gal staining of a cross section of the atherosclerotic aorta (B), X-gal and anti-Mac-3 (brown) double staining of the aortic sinus (C), X-gal and anti- α -SMA (brown) double staining of the aortic sinus (D), and X-gal and anti-CD31 (brown) double staining of the aortic sinus (E). Lu: lumen; M: media; Neo: neointima. Black arrowheads in (C-E) show LacZ-positive macrophages, smooth muscle cells and ECs, respectively. Cell nuclei are counterstained by nuclear fast red (pink). Scale bars: 50 μ m. (F) The mRNA expression of S1P receptors, S1P synthesizing and degrading enzymes in the aortas from $S1pr2^{+/+}Apoe^{-/-}$ (open bar) and $S1pr2^{-/-}Apoe^{-/-}$ (closed bar) mice. The mRNA expression levels were determined by real-time PCR. 18S rRNA was used as an internal control. Data are expressed as the ratio of the values in $S1pr2^{-/-}Apoe^{-/-}$ mice over $S1pr2^{+/+}Apoe^{-/-}$ mice ($n=3$ each).




Supplementary Figure 5.

The expression of S1P receptor mRNA in monocytes/macrophages and the Rac response to FTY-720 phosphate in macrophages. **(A)** The expression of S1P receptor mRNA in peritoneal macrophages, BM-derived macrophages, and peripheral blood monocytes from *S1pr2*^{+/+}*Apoe*^{-/-} and *S1pr2*^{-/-}*Apoe*^{-/-} mice. The mRNA expression levels of S1P receptors were determined by semi-quantitative RT-PCR. GAPDH was used as an internal control. Similar results were obtained in three different experiments. **(B)** S1PR2 deletion does not alter S1PR1-dependent Rac activation by phosphorylated FTY-720. Serum-starved peritoneal macrophages isolated from *S1pr2*^{+/+}*Apoe*^{-/-} and *S1pr2*^{-/-}*Apoe*^{-/-} mice were stimulated with phosphorylated FTY-720 (1 μM) for 10 min and subjected to pulldown assay for GTP-Rac.

A.




B.




Supplementary Figure 6.

(A) Decreased phagocytosis in *S1pr2^{-/-}Apoe^{-/-}* macrophage. Macrophages from *S1pr2^{+/+}Apoe^{-/-}*, and *S1pr2^{-/-}Apoe^{-/-}* mice were incubated with fluorescent polystyrene microspheres, fluoresbrite carboxylate, for 1 hour at 37°C. Scale bars: 20 µm. (B) Quantified data of beads uptake is shown. (n=3 each). **P*<0.05.





Supplementary Figure 7.

Effects of S1PR2 deficiency on macrophage apoptosis in peritoneal macrophages and plaque lesions in the aorta. **(A)** Phosphorylation of Akt in peritoneal macrophages from *S1pr2*^{+/+}*Apoe*^{-/-} (open bar) and *S1pr2*^{-/-}*Apoe*^{-/-} (closed bar) mice. The cells were serum-starved for 15 hours and then stimulated with S1P (0.1 μ M) for 15 minutes. Cell lysates were subjected to Western blotting using antibodies against phospho-Akt and total Akt. Quantified data of band density are shown (right). ($n=3$ each). $*P<0.05$. **(B)** Caspase-3 activation in peritoneal macrophages from *S1pr2*^{+/+}*Apoe*^{-/-} (left panel) and *S1pr2*^{-/-}*Apoe*^{-/-} (right panel) mice. The cells were treated with TNF- α (10 ng/ml) and cycloheximide (10 μ g/ml) for 12 or 24 hours. Caspase-3 activation was determined by Western blotting using anti-caspase-3 antibody that recognizes both pro-caspase-3 and cleaved caspase-3. α -Tubulin was used as an internal control. The similar observations as those in **(A)** and **(B)** were also made in bone marrow-derived macrophages. **(C)** Immunostaining using anti-cleaved caspase-3 of the atherosclerotic aortas from *S1pr2*^{+/+}*Apoe*^{-/-} (left panel) and *S1pr2*^{-/-}*Apoe*^{-/-} (right panel) mice ($n=3$ each). Quantified data of cleaved caspase-3-positive cells are shown (left). Scale bars: 50 μ m. $*P<0.05$.




Supplementary Figure 8.

S1P induces nuclear translocation of NF-κB (p65RelA). **(A)** Peritoneal macrophages from *S1pr2^{+/+}Apoe^{-/-}* mice were stimulated with 0.1 μM S1P in the presence and absence of 1 μM JTE-K1 or 10 μM Y-27632 for 2 hours. Nuclear and cytosolic extracts were subjected to Western blotting using anti-p65RelA antibody and anti-IκBα antibody. Histone H1 and α-tubulin were used as nuclear and cytosolic internal controls, respectively. **(B)** Quantified data of NF-κB protein in nucleus and IκBα in cytosol. *n*=3 each. **P*<0.05 compared with S1P-treated macrophages, #*P*<0.05 compared with non-treated macrophages. **(C)** JTE-K1 specifically inhibits S1PR2-, but not S1PR1- or S1PR3- mediated ERK activation. The CHO cells expressing each receptor were pretreated with JTE-K1 (1 μM) for 10 minutes and stimulated with S1P (0.1 μM) for 5 minutes. **(D)** TNF-α secretion by *S1pr2^{+/+}Apoe^{-/-}* and *S1pr2^{-/-}Apoe^{-/-}* macrophages. Macrophages pretreated with either JTE-K1(1 μM), Y-27632(10 μM), or BAY11-7085(10 μM) or untreated were stimulated with S1P for 12 hours. TNF-α protein levels were measured by using ELISA. (*n*=3 each). **P*<0.05 compared with non-treated macrophages, #*P*<0.05 compared with S1P-treated macrophages. **(E)** Stimulation of MYPT1 phosphorylation by HDL via S1PR2 and ROCK. *S1pr2^{+/+}Apoe^{-/-}* macrophages were pretreated with VPC23019 (1 μM) or JTE-K1 (1 μM) for 10 minutes before the addition of S1P (0.1 μM) or HDL (0.45 mg/ml), which contains the equivalent concentration of S1P, for 5 minutes. **(F)** MCP-1 stimulates chemotaxis of *S1pr2^{+/+}Apoe^{-/-}* macrophages in the presence of various concentrations of MCP-1 in the lower well of the modified Boyden chamber. (*n*=3 each). **P*<0.05.



Supplementary Figure 9.

CD11b⁺Ly6C^{hi} proinflammatory monocyte subset is not different between *S1pr2*^{+/+}*ApoE*^{-/-} and *S1pr2*^{-/-}*ApoE*^{-/-} mice. We examined surface markers in peripheral blood monocyte to examine the activation state by flow cytometry. Peripheral blood neutrophils and monocytes were defined as CD45⁺CD11b⁺Gr1⁺CD3⁻CD19⁻NK1.1⁻ and CD45⁺CD11b⁺Gr1⁻CD3⁻CD19⁻NK1.1⁻, respectively. **(A)** Scheme of CD11b⁺Ly6C^{hi} monocyte subset selection processes. **(B)** Quantified data of each population characterized of the indicated surface markers.



Supplementary Figure 10.

The expression of S1P receptor mRNA in MLECs (A) and SMCs (B) from $S1pr2^{+/+}Apoe^{-/-}$ and $S1pr2^{-/-}Apoe^{-/-}$ mice ($n=3$ each). The mRNA expression of S1P receptors was determined by real-time PCR. 18S rRNA was used as an internal control. Data are expressed as the ratio of the values in $S1pr2^{-/-}Apoe^{-/-}$ mice over S1PR1 mRNA level in $S1pr2^{+/+}Apoe^{-/-}$ mice. (C) MCP-1 secretion by MLECs. MLECs isolated from $S1pr2^{+/+}Apoe^{-/-}$ and $S1pr2^{-/-}Apoe^{-/-}$ mice, treated with or without S1P(0.1 μ M) for 12 hours. MCP-1 protein levels were measured using ELISA. ($n=3$ each). * $P < 0.05$.